Section Arrow
Quote
BIIB.NASDAQ
- Biogen
Quotes are at least 15-min delayed:2026/03/10 00:31 EDT
Regular Hours
Last
 188.24
+3.37 (+1.82%)
Day High 
188.5 
Prev. Close
184.87 
1-M High
201 
Volume 
651.63K 
Bid
181.5
Ask
198.71
Day Low
182.6 
Open
183.91 
1-M Low
181.24 
Market Cap 
27.13B 
Currency 美元 
P/E 21.03 
%Yield -- 
10-SMA 189.7 
20-SMA 191.9 
50-SMA 182.91 
52-W High 202.41 
52-W Low 110.035 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
8.79/15.77
Enterprise Value
33.71B
Balance Sheet
Book Value Per Share
124.40
Cash Flow
Cash Flow Yield
0.08
Income Statement
Total Revenue
9.89B
Operating Revenue Per Share
68.09
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
MDCXMedicus Pharma Ltd0.52+0.1348+34.99%-- 
PFEPfizer26.81-0.24-0.89%19.84PE
NVONovo-Nordisk A/S39.78+1.2+3.11%10.75PE
BMYBristol-Myers Squibb Co60.63+0.34+0.56%17.41PE
MRKMerck & Co117.11+1.32+1.14%15.9PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.